Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis

Recruitment & Eligibility

Inclusion Criteria

Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures;
- Patients older than 18 years, any ethnicity, class or social group, regardless of sex;
- Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as:
atopic dermatitis,
prurigo,
primary contact dermatitis or allergic
urticaria,
pharmacodermic,
allergic vasculitis,
dyshidrosis,

Exclusion Criteria

Patients being treated with antibiotics;
Participation in clinical trials in the 12 months preceding the survey;
Current treatment with immunosuppressants (eg, cyclosporine or methotrexate);
Current treatment with phototherapy (UVA, UVB, PUVA and lasers);
Use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion;
Topical treatments at the site of acne in the 15 days preceding the visit of inclusion;
Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion;
Presence of secondary infections at the site of treatment, diagnosed clinically;
Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich;
Pregnant or lactating women;
Chronic alcoholism;
Patients with a history of hypersensitivity to any component of the formulas of the products under investigation;
Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study;
Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical.

Study & Design

Arm && Interventions

Group	Intervention	Description
dexamethasone 0.5 mg and 1.0 mg clemastine cream	dexamethasone 0.5 mg and 1.0 mg clemastine cream	-
dexamethasone 0,5 mg cream	Dexamethasone 0,5 mg cream	-

Primary Outcome Measures

Name	Time	Method
Through clinical examinations, evaluating the efficacy of the cream composed by 0.5 mg dexamethasone and clemastine 1mg compared with the cream of 0.5 mg dexamethasone in improving the signs and symptoms associated with allergic dermatitis.	14 days

Secondary Outcome Measures

Name	Time	Method
Evaluate the safety of the formulations in relation to the occurrence, type, frequency and intensity of adverse events during treatment.	14 days
Improvement of the erythema associated with allergic dermatitis.	14 days
Improvement of the edema associated with allergic dermatitis.	14 days
Improvement of the extension of lesion associated with allergic dermatitis.	14 days
Evaluate, through clinical examinations, the effectiveness of the drug association in reducing excoriation associated with allergic dermatitis.	14 days
Evaluate, through clinical examinations, the effectiveness of the drug association in reducing exudation associated with allergic dermatitis.	14 dyas
Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of scabbing associated with allergic dermatitis.	14 days
Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of lichenification associated with allergic dermatitis.	14 days

Recruitment & Eligibility